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Abstract  
Background 
Reduced placental perfusion predisposes to the maternal syndrome pre-eclampsia 
characterized by systemically reduced perfusion. Considerable data support the role of 
angiogenic factors in the development of the maternal syndrome. Hypoxia-inducible 
factor (HIF-1) mediates the cellular responses to hypoxia e.g. by promoting 
angiogenesis. 
Methods 
Here we studied whether two single nucleotide sequence variants, c.1744 C>T that 
changes residue 582 of HIF-1α from proline to serine (P582S) and c.1762 G>A that 
changes residue 588 of HIF-1α from alanine to threonine (A588T) in the exon 12 of 
the HIF1A gene, are associated with pre-eclampsia. We studied 108 women with pre-
eclampsia in their first pregnancy, and 101 controls with normotensive pregnancies. 
Pre-eclampsia was defined as a blood pressure level of at least 140/90 mmHg in a 
woman who was normotensive before 20 weeks of gestation, and proteinuria at least 
of 0.3 g per 24-hour urine collection. The patients and controls were genotyped for 
variations in the exon 12 of HIF1A gene by sequencing 
Results 
The frequencies of the c.1744 C>T and c.1762G>A sequence variants were not 
significantly different between women with pre-eclamptic first pregnancies and 
women with normotensive pregnancies. In addition, two synonymous variants 
(c.1740G>A and c.1800A>T) were detected at comparable levels in the two groups. 
All variants were identified in the heterozygous form. 
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Conclusions 
The sequence variants in the exon 12 of the HIF1A gene were not associated with pre-
eclampsia in the Finnish population. 
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Background  
Pre-eclampsia, a pregnancy-specific vascular disorder, complicates 3% of pregnancies, 
and it may threaten the survival of both mother and baby [1]. The onset and clinical 
course is unpredictable and there are currently no predictive tests or preventive means 
available in clinical practice. Pre-eclampsia resolves after delivery, which is currently 
the only existing therapy. It is a heterogeneous disease, commonly mixed presentation 
of two categories: placental pre-eclampsia with origins primarily in abnormal placental 
perfusion and maternal pre-eclampsia with origins primarily in pre-existing problems 
in the mother [2]. Pre-eclampsia shares many common risk factors with 
atherosclerosis, such as pre-existing hypertension, diabetes, obesity, renal disease and 
the metabolic syndrome [3]. A large body of evidence also suggests that pre-eclampsia 
is associated with increased risk of cardiovascular diseases in later life of both mother 
and baby [4, 5]. Twin studies have shown that genetic factors account more than 50% 
of an individual’s susceptibility to pre-eclampsia [6]. Despite intensive research 
genetic factors predisposing pre-eclampsia are largely unknown [7, 8]. 
Abnormalities in the angiogenic balance have been proposed to as having 
a major role in the molecular cascade causing maternal endothelial dysfunction and 
systemically reduced perfusion in pre-eclampsia [9]. Hypoxia-inducible factor (HIF-1) 
is a transcriptional activator that plays important role in physiologic responses to 
hypoxia, and the pathophysiology of common human diseases such as ischemic 
cardiovascular disease, cancer, pre-eclampsia and intrauterine growth restriction 
(IUGR) [10]. HIF-1 is a heterodimer consisting of an oxygen-regulated HIF1-α 
subunit and a constitutively expressed HIF1-β subunit [10]. The HIF-1 heterodimer 
recognizes HIF-response elements within the promoter regions of hypoxia-responsive 
target genes. More than 100 target genes that are involved in angiogenesis, vascular 
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tone, glucose metabolism, cell proliferation, cell survival and apoptosis are known to 
be regulated by this mechanism [11]. Under normoxic conditions, the alpha subunit is 
rapidly degraded by means of ubiquitination and proteosomal degradation [12, 13]. 
HIF1-α protein levels are regulated by the von Hippel –Lindau protein, which targets 
the N-terminal transactivation domain (N-TAD) within the oxygen-dependent 
degaradation domain (ODD) of HIF1-α [12, 14]. 
Two non-synonymous single nucleotide sequence variants, rs11549465 
and rs11549467, in the exon 12 of the HIF1A gene cause amino acid substitution 
within (rs11549465) or near (rs11549467) the minimal N-terminal transactivation 
domain (N-TAD) within the ODD that mediates interactions with the von Hippel-
Lindau protein, which in turn targets HIF1-α for degradation (Figure 1) [15]. We 
studied whether these sequence variants, rs11549465 (c.1744 C>T) that changes 
residue 582 of HIF-1α from proline to serine (Pro582Ser) and rs11549467 (c.1762 
G>A) that changes residue 588 of HIF-1α from alanine to threonine (Ala588Thr) in 
the exon 12 of the HIF1A gene, are associated with pre-eclampsia. 
 
Methods 
Patients 
108 women with pre-eclampsia in their first pregnancy, and 101 controls with at least 
one normotensive pregnancy were included in this study. This is a retrospective 
analysis of stored DNA samples. The study population has been previously described 
[16].  
Before their first pregnancy, both patients and controls have been healthy and no 
evidence of renal or autoimmune disease could be detected. Pre-eclampsia was defined 
using the following criteria; 1) blood pressure (BP) level at least 140/90 mmHg, and 2) 
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proteinuria at least 0.3 g per 24-hour urine collection [17]. The blood pressure was 
checked by two measurements with at least 6 hours apart and proteinuria was 
confirmed after gestation week 20. Pre-eclampsia was defined as severe in 95 women 
who also fulfilled one or more of the following criteria included in the severity 
predictors of the National High Blood Pressure Education Working Group: systolic BP 
at least 160 mmHg, diastolic BP at least 110 mmHg, or proteinuria at least 2 g during 
any 24-hour urine collection [18]. 
The blood samples were collected between January 1997 and April 1998 from women 
who, according to discharge records of the Helsinki University Central Hospital, had 
had severe pre-eclampsia between 1988 and 1998. The control samples were collected 
from women with uncomplicated pregnancies who gave birth at the Helsinki 
University Central Hospital. Patients and controls are of Finnish (Caucasian) origin. 
This study has been approved by the local ethical review committee and an informed 
consent was obtained from all the study subjects. The clinical characteristics of the 
patients are presented in Table 1. 
Genotyping 
Genomic DNA was extracted from 10 ml of peripheral blood using a phenol-
chlorophorm method. PCR amplification of the exon 12 of the HIF1A gene was 
performed using forward and reverse primers 5'-CAGAAGCAAAGAACCCAT-3' (F) 
and 5'-TCAAGAATTTGCGTTAG-3' (R), described by Resar et al. (2005) [19].  The 
reaction was done in a 50 µl volume containing 70 ng genomic DNA, 30 pmol of each 
primer, 10 mM Tris-HCl, pH 8.8, 1.5 mM MgCl2, 50 mM KCl and 0.1% Triton X-100, 
10 nmol of each nucleotide (dNTP) and 0.75 U Dynazyme polymerase-enzyme 
(Finnzymes Oy, Espoo, Finland). Polymerase chain reaction conditions were as 
follows: 4 min at 94 °C followed by 35 cycles of denaturation step: 30 s at 94 °C; 
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annealing step: 30 s at 49 °C; elongation step: 30 s at 72 °C; and final extension for 10 
min at 72 °C terminated the reaction after final annealing. Amplifications were 
performed in a DNA 2720 Thermal Cycler (ABI, Foster City, CA, USA). 
Sequencing of the PCR amplicons were performed using Big Dye Terminator kit 
(version 3.1) supplied by Applied Biosystems (ABI, Foster City, CA, USA). The 
reactions were run on an ABI 3730 capillary sequencer according to the manufacturer's 
instructions. 
Statistics and study power 
The minor allele frequencies of the r rs11549465 and rs11549467 are 0.092 and 
0.018, respectively, in the CEPH population (Utah residents with ancestry from 
northern and western Europe) (www.hapmap.org). Our sample size has 80% power 
to detect a relative risk 2.2 for the rs11549465 variant , and a relative risk 2.7 for 
the rs11549467 variant in the HIF1A gene at a significance level α=0.05.  
Statistical analyses were performed using GraphPad Prism 4 (GraphPad software 
Inc., CA, USA). The association between the polymorphisms and pre-eclampsia 
was estimated by comparing the frequencies in the two study groups.  The 
statistical significance of the different proportions was measured using Fisher’s 
exact test.  Parametric and non-parametric tests were used as appropriate for the 
continuous clinical data.  Differences were considered as statistically significant 
for P values <0.05. To determine if genotype frequencies deviate from the the 
Hardy-Weinberg Equilibrium (HWE) a X 2 test was performed (www.oege.org). 
Results  
As a result of sequencing exon12 of the HIF1A gene and the flanking exon-intron 
boundaries of HIF1A four exonic sequence variants were detected. All the variants in 
both patients and controls were detected in a heterozygous state. All four SNP 
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genotype frequencies in both patients and controls were in agreement with Hardy-
Weinberg equilibrium (p>0.05.) 
No statistical differences were shown when comparing the frequencies of the non-
synonymous sequence variants, rs11549465 and rs11549467 between patients and 
controls. Table 2 shows locations of the detected variants, their effect on the protein, 
and number of alleles in patients and controls. Numbering of the base positions is 
relative to the adenine in the ATG startcodon of the HIF1A gene. 
In addition to two non-synonymous sequence variants, we found two synonymous 
sequence variants (Figure 1). Variant rs34005929 (c.1740 G>A), a synonymous 
change of the last nucleotide of codon 580 encoding a leucine, was detected in two 
patients but in none of the controls. Variant c.1800 A>T is changing the last nucleotide 
of codon 600 (Thr), and is predicted to be a silent polymorphism. This variation was 
detected in four patients and two controls. According to our knowledge this sequence 
variant has not been reported in public databases. 
Discussion  
In this study performed in the genetically homogenous Finnish population, we found 
that the allele distribution of the two non-synonymous sequence variants, rs11549465 
(c.1744 C>T, Pro582Ser) and rs11549467 (c.1762 G>A, Ala588Thr), in the exon 12 of 
the HIF1A gene was not different between women with pre-eclamptic first pregnancies 
and controls with normotensive pregnancies. We also found two synonymous 
sequence variants in the exon 12 of HIF1A gene: rs34005929 (c.1740 G>A, 
Leu580Leu) and variant c.1800 A>T (Thr600Thr) which has not previously been 
reported in public databases.  
HIF-1α is known to play role in the normal development and pathology of 
placenta as a regulator of responses to hypoxia. Accumulation of HIF-1α protein in 
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the pre-eclamptic placentas occurs as a consequence of both increased formation 
secondary to relative ischemia/hypoxia and reduced degradation after 
reperfusion/oxygenation due to proteosomal dysfunction [20]. Overexpression of 
HIF-1α protein in placenta contributes to the dysregulation of numerous genes [21]. 
Abnormalities in the angiogenic balance have been proposed to as having a major role 
in the molecular cascade causing maternal endothelial dysfunction and systemically 
reduced perfusion in pre-eclampsia [9], which makes HIF1A an interesting gene in 
contributing the maternal response to reduced placental perfusion. 
Pre-eclampsia originates in the placenta but the target organ is maternal 
endothelium. Endothelial dysfunction, a central feature in pre-eclampsia, has been 
suggested to be a part of a more generalized inflammatory reaction [22]. Innate 
immune response has been linked to the hypoxic response through transcriptional 
regulation of HIF-1α by transcription factor NF-κB [23].  
Pre-eclampsia increases the risk of future ischemic heart disease [24]. This 
could be an inherent propensity in these women, or vascular damage may have 
occurred as a consequence of the pre-eclamptic pregnancy. HIF1A is one of the genes 
of importance in the pathways mediating the response to ischemia. The rs11549465 
sequence variant was more common in patients who presented with stable exertional 
angina rather than acute myocardial infarction [25]. These authors suggested that the 
reduced activity of the variant form of HIF1A could reduce plaque neovascularization 
and the risk of intraplaque hemorrhage and of subsequent acute myocardial infarction 
[25]. 
The results of the functional studies of the sequence variants in the HIF1A gene 
in different tissues as well as, the effect of these variants in angiogenesis are 
inconclusive. The rs11549465 and rs11549467 variants of the HIF1A gene have been 
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shown to have enhanced transcription activities in in vitro studies under both normoxic 
and hypoxic conditions [26,27]. Rs11549465 variant was associated with increased 
tumor microvessel density in head and neck cancer [26], and in prostate cancer [27]. 
The expression of some down-stream genes that are under the transcription control of 
HIF-1α (LDH-5, VEGF, GLUT1) was not increased in the presence of the rs11549465 
variant in non-small cell lung cancer samples studied by immunohistochemistry [28]. 
In the presence of rs11549465 variant the formation of collaterals in patients with 
ischemic heart disease was impaired [19].  
To the best of our knowledge this is the first study to investigate whether the 
two non-synonymous sequence variants that lie within or near the N-TAD within the 
ODD in the exon 12 of the maternal HIF1A gene are associated with the pre-
eclamptic phenotype.  
These sequence variants are interesting because polymorphisms that reduce 
the activity of HIF-1α as a transcriptional activator could underlie pre-eclampsia by 
causing inadequate placental vascularisation in the early pregnancy which later leads 
to hypoxia in the placenta. We are not aware of studies comparing the frequency of 
these sequence variants between the pre-eclamptic placentas and placentas from 
normotensive pregancies, or studies measuring the HIF-1α levels in placentas 
heterozygous of homozygous for these sequence variants. 
This retrospective study has several limitations. First, we did not have fetal 
DNA samples. Consequently, we were neither able to study the effect of fetal/placental 
genotype nor the maternal fetal genotype interaction. The other limitation is inadequate 
statistical power to detect small genotypic effects. Under a dominant model, the 
sample size provides 80% power to detect a genotype relative risk over 2.2, which is 
much higher than the risk conferred by the majority of susceptibility genes detected to 
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date for complex disorders. For detection of small genotypic effects studies in larger 
sample sets are warranted. Further studies are also warranted to elucidate effects of the 
functional polymorphisms in HIF1A on the pathogenesis of maternal and placental 
pre-eclampsia. Pre-eclampsia involves complex interaction between placentation, 
vascular function and maternal metabolism. Thus, research and recognition of genes, 
such as HIF1A, and thereby biochemical components critical for such interactions 
increase our understanding of the molecular mechanisms leading from cellular hypoxia 
to metabolic changes. 
Conclusions  
Our data suggest that the sequence variants in the exon 12 of the HIF1A gene are not 
associated with pre-eclampsia in the Finnish population. The study has inadequate 
statistical power to detect small genotypic effects. Therefore, this gene should be 
assessed in bigger studies. Further studies are also warranted to elucidate possible 
fetal genotypic effects. 
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Figures 
Figure 1  - Structure of the HIF-1α protein, and polymorphisms identified by 
sequencing the exon 12 of the HIF1A gene. bHLH=basic-helix-loop-helix domain, 
PAS= Per-Arnt-Sim domain, ODD=oxygen dependent degradation domain, N-TAD= 
N-terminal transactivation domain, C-TAD= C-terminal transactivation domain. 
Rs11549465 changes residue 582 of HIF-1α from proline to serine (P582S), and 
rs11549467 changes residue 588 of HIF-1α from alanine (A) to threonine (T). Variant 
rs34005929 is a synonymous change of the last nucleotide of codon 580 encoding a 
leucine (L). Variant changing the last nucleotide of codon 600 (T) is predicted to be a 
silent polymorphism. 
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Tables 
Table 1  - Clinical Characteristics 
  Pre-eclampsia 
(N=108) 
Controls (N=101)  
    
Variable Mean (95% CI) Mean (95% CI) P 
    
Age (y) 29.5 (28.5, 30.4) 29.9 (28.9.0, 30.9) NS 
BMI (kg/m2) 22.6 (22.0, 23.2) 22.6 (21.6, 23.5) NS 
Systolic blood pressure 
(mmHg) 
171 (168, 175) 119 (117, 121) <0.0001 
Diastolic blood pressure 
(mmHg) 
107 (105, 108) 73 (72, 75) <0.0001 
Proteinuria (g/24 h) 7.5 (5.9, 9.1)    
Birth weight (SD) -1.5 (-1.7, -1.3) -0.2 (-0.4, -0.1) <0.0001 
Weeks of gestation 34.5 (33.7, 35.3) 39.6 (39.4, 39.9) <0.0001 
CI=confidence interval 
NS= non significant 
 
Table 2  - Non-synonymous sequence variants within the oxygen-dependent 
degradation domain of the HIF1A gene with pre-eclamptic first pregnancies 
(N=108) and women with normotensive pregnancies (N=101) 
Variation Amino acid No.of alleles 
in cases 
No. of alleles 
in controls  
P-value* OR 
(95% CI) 
 
rs11549465 
(c.1744C>T) 
     
C allele Pro582 208 189 0.26 0.56 (0.23-1.38) 
T allele Ser582 8 13   
 
rs11529467 
(c.1762G>A) 
     
G allele Ala588 212 199 1.00 1.25 (0.28-5.66) 
A allele Thr588 4 3   
*Fisher’s exact test 
 
Figure 1
